Table 2.
The relationship between lncUSMycN expression levels and clinicopathological features of patients with breast cancer
| Characteristics |
No. of
patients (%) |
lncUSMycN
ΔCt mean ± SEM |
p
value |
|---|---|---|---|
| Age <45 >45 |
24 (46.7) 28 (53.3) |
18.11 ± 0.86 17.13 ± 0.70 |
0.379 |
| Tumor Size <2 cm >2 cm |
24 (46.2) 20 (38.5) |
16.34 ± 0.72 18.04 ± 0.92 |
0.148 |
| TNM* clinical stage I II III |
17 (32.7) 14 (26.9) 14 (26.9) |
15.80 ± 0.92 16.43 ± 1.06 20.28 ± 0.88 |
0.004 ** |
| Lymphatic methastasis Absent Present |
17 (32.7) 28 (53.8) |
15.79 ± 0.92 18.11 ± 0.72 |
0.052 |
| Differentiation Poor Moderate Well |
5 (9.6) 35 (67.3) 5 (9.6) |
14.16 ± 1.53 17.58 ± 0.63 17.91 ± 2.31 |
0.176 |
| Progestron expression (%) <30 |
18 (34.6) 16 (30.8) |
17.54 ± 0.95 16.31 ± 1.02 |
0.38 |
| Estrogen expression (%) <30 >30 |
17 (32.7) 17 (32.7) |
18.16 ± 0.81 15.77 ± 1.07 |
0.085 |
| HER-2 status Negative Positive |
16 (30.8) 15 (28.8) | 16.86 ± 1.04 17.14 ± 1.10 |
0.858 |
| Location Right Left |
20 (38.5) 23 (44.2) |
16.68 ± 0.88 18.12 ± 0.73 |
0.214 |
**
The value in bold is significant (p <0.01)